However, when we divided the cohorts based on APOE4 status (a well-known AD risk factor), the APOE4 carriers in Cohort I demonstrated significantly lower IAPPO-IgA levels compared with non-carriers. The gene discussed is CD79A; the disease is Alzheimer disease.